Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in European colloid solutions.

Hans-Jürgen Dieterich1

  • 1Department of Anesthesiology and Intensive Care Medicine, Tuebingen University Hospital, Germany. hjdieter@med.uni-tuebingen.de

The Journal of Trauma
|May 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity of the lipoxygenase inhibitor 1-phenyl-3-pyrazolidinone (phenidone) and derivatives on the inhibition of adhesion molecule expression on human umbilical vascular endothelial cells.

Biologics : targets & therapy·2009
Same author

Effects of 1400W and/or nitroglycerin on renal oxygenation and kidney function during endotoxaemia in anaesthetized rats.

Clinical and experimental pharmacology & physiology·2009
Same author

Low-dose dexamethasone-supplemented fluid resuscitation reverses endotoxin-induced acute renal failure and prevents cortical microvascular hypoxia.

Shock (Augusta, Ga.)·2008
Same author

Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study.

Pain medicine (Malden, Mass.)·2008
Same author

A pilot open-label study of the efficacy of subanesthetic isomeric S(+)-ketamine in refractory CRPS patients.

Pain medicine (Malden, Mass.)·2008
Same author

Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia.

Critical care medicine·2006
Same journal

Article.

The Journal of trauma·2014
Same journal

Article.

The Journal of trauma·2014
Same journal

Program schedule for the sixty-fifth annual meeting of the american association for the surgery of trauma.

The Journal of trauma·2014
Same journal

Letters to the editor.

The Journal of trauma·2014
Same journal

Posttraumatic brachial plexitis.

The Journal of trauma·2011
Same journal

Incidental findings in focused assessment with sonography for trauma in hemodynamically stable blunt trauma patients: speaking about cost to benefit.

The Journal of trauma·2011
See all related articles

New hydroxyethyl starch (HES) solutions with modified molecular structures show reduced impact on blood coagulation. Research also focuses on minimizing inflammatory responses and improving HES persistence in circulation.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Critical Care Medicine

Background:

  • High-molecular-weight, highly substituted hydroxyethyl starch (HES) solutions are associated with coagulopathy.
  • These HES formulations are the only starch-based synthetic colloids approved in the United States for volume replacement.
  • Current research trends in European colloid solutions involve the development of novel starch molecules.

Purpose of the Study:

  • To introduce a new HES solution with a molecular weight of 130,000, an increased C2:C6 ratio, and a molar substitution of 0.4.
  • To evaluate the impact of this new HES formulation on coagulation parameters.
  • To explore strategies for modulating the inflammatory response and enhancing the intravascular persistence of colloid solutions.

Main Methods:

Related Experiment Videos

  • Development of a novel HES molecule with specific structural modifications (increased C2:C6 ratio, reduced molar substitution).
  • Administration of the new HES solution and assessment of its influence on coagulation.
  • Experimental investigation into the modulation of monocyte and endothelial cell inflammatory responses to colloid infusion.

    • Main Results:

    • The newly developed HES solution (130,000 molecular weight, modified substitution) demonstrated no significant influence on coagulation.
    • Experimental work is ongoing to modulate inflammatory responses and improve intravascular persistence of colloids.

    Conclusions:

    • Novel HES formulations with tailored molecular characteristics can mitigate the coagulopathic effects observed with older HES products.
    • Future research directions include targeting inflammatory pathways and prolonging the efficacy of synthetic colloids.